Reported 22 days ago
As the Federal Reserve's rate-cutting spurs a shift toward high-yield dividend stocks, Pfizer's stock—with its attractive 5.9% dividend yield and low valuation—presents a strong opportunity for long-term investors. Despite underperforming the S&P 500 in 2024, Pfizer is seeing robust revenue growth in its non-COVID products, particularly within oncology, thanks to recent acquisitions and market share gains. Value-oriented investors might find that Pfizer's current stock price does not reflect its operational success and potential for future growth.
Source: YAHOO